| Income Statement | 2025-09-30 | 2025-03-31 | 2024-09-30 | |
|---|---|---|---|---|
| Derivative warrant liabilities gain | 3,784 | 2,261 | 2,880 | |
| Income from continuing operations before income tax expense | 1,965 | 3,818 | 1,498 | |
| Income tax expense | 0 | -122 | 405 | |
| Net income from continuing operations | 1,965 | 3,940 | 1,093 | |
| Net income (loss) from discontinued operations, net of tax | - | - | 381 | |
| Net income from discontinued operations, net of tax | 0 | 54 | - | |
| Net income | 1,965 | 3,994 | 1,474 | |
| Basic - net income (in dollars per share) | 0.21 | 0.65 | 0.24 | |
| Basic weighted-average common shares outstanding (note 17) (in shares) | 9,441,073 | 6,134,634 | 6,068,019 | |
| Diluted - net loss (in dollars per share) | -0.08 | 0.21 | -0.15 | |
| Diluted weighted-average common shares outstanding (note 17) (in shares) | 19,476,635 | 8,204,453 | 9,099,601 | |
AYTU BIOPHARMA, INC (AYTU)
AYTU BIOPHARMA, INC (AYTU)